CSIMarket Company Name, Ticker, Suppliers, else..
 
Aim Immunotech Inc   (NYSEAMER: AIM)
 
Price: $0.2300 $0.00 0.000%
Day's High: $0.23999999463558197 Week Perf: 0.00
Day's Low: $ 0.23 30 Day Perf: -14.81 %
Volume (M): 8,542,400 52 Wk High: $ 2.89
Volume (M$): $ 0 52 Wk Avg: $1.04
Open: $0.23 52 Wk Low: $0.19



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 4
 Employees 21
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 5
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aim Immunotech Inc is a biotechnology company that focuses on the development and commercialization of novel drugs for the treatment of various diseases. The company's main focus is on developing therapies that modulate the immune system to fight diseases such as cancer, viral infections, and immune disorders. Aim Immunotech Inc utilizes its proprietary technology called Ampligen to stimulate the immune response and enhance the effectiveness of immunotherapies. The company's goal is to provide innovative and effective treatment options for patients with unmet medical needs.


   Company Address: 2117 SW Highway 484 Ocala 34473 FL
   Company Phone Number: 448-7797   Stock Exchange / Ticker: NYSEAMER AIM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
PFE        1.75% 
PRGO        3.04% 
• View Complete Report
   



Clinical Study

AIM ImmunoTech Pioneering Combinatorial Therapies in Oncology and Infectious Disease

Published Mon, Nov 10 2025 2:45 PM UTC

In the evolving landscape of oncology and infectious disease management, AIM ImmunoTech Inc. (NYSE American: AIM) has recently captured attention by detailing significant findings from completed clinical trials. The company, primarily known for its innovative immunotherapy, Ampligen (rintatolimod), has contributed to our understanding of treatment modalities in advanced recu...
Clinical Study

Ampligen From Cancer to Viral Defense, A Frontier of Therapeutic Innovation,

Published Tue, Nov 4 2025 10:01 PM UTC

Ampligen: A Promising Player in the Fight Against Cancer and Viral Infections AIM ImmunoTech Inc. continues to push the frontiers in the field of immunotherapy, with a series of compelling announcements highlighting the utility of Ampligen (rintatolimod) in combating difficult-to-treat diseases. The latest revelations about Ampligen were showcased in a late-breaking abstract...
Management Announcement

AIM ImmunoTech Faces Financial Headwinds as It Postpones Offering Amidst Ambitious Healthcare Goals,

Published Tue, Feb 11 2025 1:30 PM UTC

AIM ImmunoTech Inc.: Navigating Financial Turbulence Amidst Strategic Ambitions in the Post-COVID Healthcare LandscapeIn a recent press release dated February 11, 2025, AIM ImmunoTech Inc. (NYSE American: AIM) made a crucial announcement concerning its financial offerings. The biotechnology firm revealed that it would be postponing any offering under its Registration Stateme...
Management Announcement

AIM ImmunoTechs Tumultuous Road: High Hopes vs Historic Losses in the Post-COVID Healthcare Landscape

Published Wed, Jan 15 2025 2:05 PM UTC

AIM ImmunoTech s Tumultuous Road: High Hopes vs. Historic Losses in the Post-COVID Healthcare LandscapeAIM ImmunoTech Inc. a biotechnology company known for its work on the immunotherapy drug Ampligen (rintatolimod), has made an ambitious bid for redemption as it navigates the complexities of the post-COVID healthcare era. The company recently released a bullish commentary o...
Stock Market Announcement

Navigating Compliance and Market Challenges: AIM ImmunoTechs Strategic Bid for Redemption in Post-COVID Therapeutics,

Published Tue, Dec 17 2024 9:45 PM UTC

AIM ImmunoTech s Compliance Strategy Amidst Market Struggles: Navigating Noncompliance and Patent Expansion in Post-COVID TreatmentIn a recent press release, AIM ImmunoTech Inc. announced its receipt of a notification from the NYSE American regarding noncompliance with continued listing standards. This notification underscores the pressures the company faces as it attempts t...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 10.65
Price to Sales (Expected) -
Price to Book 0.47
PEG (TTM) -

Financial Strength Current
Quick Ratio 1
Working Capital Ratio 1.06
Leverage Ratio (MRQ) 3.04
Total Debt to Equity 1.98
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -5.38 $
Revenues (TTM) 0.02 $
Cash Flow (TTM) 1.13 $
Cash 1.35 $
Book Value 0.49 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 4,476
Net Income per Employee (TTM) -632,190
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.02

Profitability Ratios Current
Gross Margin (MRQ) 81.82 %
Operating Margin (MRQ) -10118.18 %
Net Margin (MRQ) -13740.91 %
Net Cash Flow Margin (MRQ) 12868.18 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Aim Immunotech Inc's Segments





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.